⚠️ Research Use Only. BPC-157 10mg is supplied strictly for in-vitro laboratory research. It is not intended for human consumption, therapeutic, diagnostic, or clinical use. All information below reflects peer-reviewed preclinical and scientific literature only. This content is not medical advice. Ascend Peptides UK accepts no liability for misuse of this product
Few research peptides have generated as much consistent scientific attention as BPC-157. This guide is a laboratory reference specifically for the 10mg research format: what makes it a practical quantity for established research programmes, how the strength of the published evidence varies across its documented mechanisms, and what to verify before sourcing a batch for in-vitro work.
For the full structural and mechanistic overview of the compound itself, see What Is BPC-157? This guide assumes that background and focuses on considerations specific to the 10mg research format.
Ascend Peptides UK supplies BPC-157 10mg as a high-purity research peptide for laboratory investigation only. All information in this guide is provided strictly for scientific and educational purposes. This compound is not intended for human consumption, clinical use, or therapeutic application.
BPC-157: Quick Structural Reference
BPC-157 (Body Protection Compound 157) is a synthetic pentadecapeptide — a chain of 15 amino acids — derived from a partial sequence of a protein found naturally in human gastric juice. The sequence is Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val, with a molecular weight of approximately 1,419 Daltons.
The compound shows notable stability in biological environments, including resistance to hydrolysis under acidic conditions — a property that has made it a useful subject for peptide stability research as well as a compound of interest across several laboratory disciplines. For the complete breakdown of its structure, origin and research applications, see What Is BPC-157?
Evidence Strength in BPC-157 Research: What’s More Consistently Reported vs. Preliminary
No specific receptor for BPC-157 has been conclusively identified to date — an important caveat for researchers designing receptor-binding studies, since it distinguishes this compound from peptides with a well-defined single-receptor mechanism. Published laboratory research has instead documented interactions across multiple molecular pathways, and these vary considerably in how consistently they have been reported across independent studies. The evidence base for all of these pathways is predominantly preclinical (animal and in-vitro); repeated findings across such models are not equivalent to robust human validation, and human clinical evidence for BPC-157 remains very limited.
Findings More Consistently Reported in the Preclinical Literature
Nitric oxide (NO) system modulation: the mechanism reported most consistently across published preclinical studies. Multiple research groups have documented interactions between this peptide and the nitric oxide pathway, which plays a central role in vascular biology, inflammation signalling and cellular communication.
Growth factor upregulation (VEGF pathway): also reported across multiple preclinical models, with documented interactions between BPC-157 and vascular endothelial growth factor and related growth factors involved in angiogenesis.
More Preliminary Findings — Documented But Less Consistently Reported
FAK-paxillin pathway: research has identified activation of the focal adhesion kinase (FAK) and paxillin signalling pathway, involved in cell migration and tissue organisation. The evidence base here is smaller and warrants cautious interpretation.
Neurotransmitter system interactions: published research has examined interactions with dopaminergic, serotonergic and GABAergic systems in animal models. These findings are documented but derive predominantly from animal studies.
Tendon and ligament fibroblast activity: in vitro studies have examined how this compound affects fibroblast behaviour, the cells responsible for producing collagen and extracellular matrix components. Replication across independent research groups remains more limited in this area.
It is important to note that the majority of this mechanistic research has been conducted in cell culture and animal models, with a significant proportion originating from a single research group. None of this research constitutes clinical evidence of efficacy in humans, and researchers should weigh the strength of each finding accordingly when designing new studies.
Where BPC-157 10mg Is Applied in Laboratory Research
BPC-157 10mg has been applied across connective tissue and musculoskeletal research, gastrointestinal biology, angiogenesis and vascular research, neurobiological research, and inflammation and cellular signalling research — each area drawing on one or more of the mechanisms outlined above. For the complete breakdown of each application area, see What Is BPC-157?
BPC-157 is sometimes incorporated alongside TB-500 in multi-compound recovery research protocols, since the two compounds act through mechanistically independent pathways. For a full structural and mechanistic comparison, see the TB-500 vs BPC-157 research peptide comparison guide.
Understanding the BPC-157 10mg Research Format
10mg is a vial/product format rather than an intrinsic scientific property of BPC-157. The BPC-157 10mg research format is used by some established research programmes for several practical reasons:
Sufficient volume for multi-run studies: 10mg provides enough material to conduct multiple experimental assays, concentration-response studies, or comparative investigations without requiring frequent reordering, reducing batch-to-batch variability in research results.
Cost efficiency for established programmes: for research groups with confirmed demand, the 10mg format offers better value per milligram than smaller quantities whilst remaining manageable in terms of storage and usage planning.
Frequently referenced in published literature: a substantial proportion of published laboratory research referencing this compound uses quantities in this range, which can make it easier to align experimental protocols with existing scientific literature.
Compatible with lyophilised storage: at 10mg, the lyophilised powder format maintains stability when stored at -20°C, preserving peptide integrity across the duration of a research programme.
For researchers undertaking preliminary or exploratory work, smaller quantities may be more appropriate. For programmes with a confirmed experimental direction, the 10mg format is a practical and widely available option — though the appropriate quantity always depends on the specific experimental design.
BPC-157 10mg Research-Grade Verification: Purity and Identity Testing
Because BPC-157 is one of the more heavily counterfeited compounds in the UK research peptide market, batch-specific verification matters more here than for lower-demand compounds. Two checks are non-negotiable for serious laboratory work:
HPLC purity verification: research-grade purity should be 98% or above, confirmed by High-Performance Liquid Chromatography and documented with a batch-specific Certificate of Analysis.
Mass spectrometry identity confirmation: molecular weight must be verified via LC-MS to confirm the peptide sequence matches the expected 15-amino acid structure and the confirmed molecular weight of approximately 1,419 Daltons.
Ascend Peptides UK supplies BPC-157 10mg with full analytical documentation covering HPLC purity and LC-MS identity, batch traceability, and same-day UK dispatch for orders received before 4pm. For the complete documentation framework this is checked against, see the research grade standards and how we test peptides pages, and the batch-specific results themselves on the batch verification page.
Endotoxin Testing as a Research-Quality Consideration
For any application involving live cell systems, endotoxin contamination is a recognised research-quality consideration: even low levels can trigger unintended inflammatory signalling in cell-based assays, confounding results — a point particularly relevant given how frequently BPC-157 is used in cell-based angiogenesis and fibroblast assays. Endotoxin testing (via the Limulus Amebocyte Lysate, or LAL, method) is one way researchers address this in their own experimental design.
Ascend Peptides UK’s published Certificates of Analysis for BPC-157 confirm HPLC purity and LC-MS molecular identity; endotoxin testing is not currently a standard field on these CoAs. Researchers whose experimental design requires LAL-tested material for live-cell work should confirm this specific requirement directly before use, rather than assuming it is covered by standard batch documentation.
Handling and Storage Reference
BPC-157 10mg is supplied in lyophilised (freeze-dried) powder form. Lyophilised powder should be stored at -20°C, protected from excessive heat, direct light and moisture, until required for reconstitution.
Reconstitution method and solvent selection should be determined by the qualified researcher according to the specific requirements of the experimental design. Refer to the current product-specific handling documentation for reconstitution guidance rather than any single external source.
Regulatory Compliance and Research Responsibility
BPC-157 is classified as a research chemical in the United Kingdom. It is not a licensed medicine, is not approved for human consumption, and must not be used in any clinical, therapeutic or diagnostic context.
BPC-157 is not currently listed as a controlled substance under UK law. The regulatory landscape for research peptides continues to evolve, however, and buyers are strongly advised to verify the current legal and regulatory status of this compound independently — consulting a qualified regulatory professional or their institution’s compliance team — rather than relying solely on any single source of information, including this guide.
All purchasing researchers and institutions are fully responsible for ensuring their use of this compound complies with applicable UK legislation and any institutional ethics requirements. Ascend Peptides UK provides fully compliant, research-only labelled products and makes no health, clinical or performance-related claims about any compound in our range.
Conclusion
The BPC-157 10mg research format is a practical option for one of the more extensively studied synthetic peptides in current laboratory research. Its suitability for multi-run studies, frequent reference in published literature, and compatibility with long-term lyophilised storage make it a practical option for research programmes with a confirmed experimental direction.
Researchers working with this compound should remain mindful of the evidence context outlined in this guide: the nitric oxide and VEGF pathway findings are reported more consistently than the other documented pathways, several other documented interactions represent a more preliminary evidence base, no specific receptor has been conclusively identified, and the majority of published research derives from animal models with a significant proportion from a single research group. Human clinical evidence remains very limited throughout. These are not reasons to dismiss the compound’s research value — they are the markers of a field that remains preclinical, active and developing.
For researchers and laboratories across the United Kingdom sourcing BPC-157 10mg, Ascend Peptides UK provides research-grade purity standards with full batch documentation, HPLC-verified purity, LC-MS identity confirmation, and same-day UK dispatch.
Frequently Asked Questions About BPC-157 10mg
Why is the BPC-157 10mg research format used?
The 10mg vial format provides sufficient material for multiple experimental runs without frequent reordering, is frequently referenced in published laboratory research, offers better cost efficiency per milligram for established programmes, and maintains stability in lyophilised storage at -20°C across a typical research project. It is a vial/product format rather than an intrinsic property of the compound, and the appropriate quantity depends on the specific experimental design.
How does the evidence for BPC-157’s research mechanisms vary in strength?
The nitric oxide signalling system and the VEGF pathway are reported more consistently across preclinical studies than the other documented pathways. Other documented interactions — including the FAK-paxillin pathway, tendon and ligament fibroblast activity, and dopaminergic, serotonergic and GABAergic neurotransmitter interactions — represent a more preliminary evidence base and warrant cautious interpretation. All of this evidence is preclinical; no specific receptor for BPC-157 has been conclusively identified, and human clinical evidence remains very limited.
What purity standards and endotoxin-testing considerations apply to BPC-157 10mg?
Research-grade BPC-157 should be at least 98% pure, confirmed by HPLC analysis, with molecular identity verified via LC-MS — both of which are documented on Ascend Peptides UK’s published, batch-specific Certificate of Analysis for BPC-157 10mg. For live-cell applications, endotoxin testing (via the LAL assay) is a further research-quality consideration some laboratories require; this is not a standard field on every supplier’s CoA, so confirm it directly if your experimental design depends on it.
What is the molecular weight of BPC-157?
BPC-157 has a molecular weight of approximately 1,419 Daltons, consisting of 15 amino acids with the sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. Molecular weight and sequence identity should always be confirmed via mass spectrometry data included in the batch Certificate of Analysis.
Where can I buy BPC-157 10mg in the UK?
BPC-157 10mg is available from Ascend Peptides UK. We are a UK-based peptide supplier providing research-grade BPC-157 with HPLC-verified purity, LC-MS identity confirmation, full batch documentation, and same-day dispatch for orders placed before 4pm. All products are supplied for laboratory research use only.
For broader questions about BPC-157 itself — including its full mechanism, legal status and general research applications — see the FAQ on What Is BPC-157?
Scientific References
Sikiric, P., Seiwerth, S., Grabarevic, Z., Petek, M., Rucman, R., et al. (1994). “The beneficial effect of BPC 157, a 15 amino acid peptide BPC fragment, on gastric and duodenal lesions induced by restraint stress, cysteamine and 96% ethanol in rats. A comparative study with H2 receptor antagonists, dopamine promotors and gut peptides.” Life Sciences, 54(5), PL63–68.
Chang, C. H., et al. (2011). “The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration.” Journal of Applied Physiology, 110(3), 774–780.
Sikiric, P., et al. (2011). “Stable gastric pentadecapeptide BPC 157: novel therapy in gastrointestinal tract.” Current Pharmaceutical Design, 17(16), 1612–1632. This is a review article synthesising earlier preclinical findings; it is cited here as a secondary source summarising the field, not as independent primary evidence.
DISCLAIMER
All products supplied by Ascend Peptides UK are intended strictly for research purposes only. They are not intended for human consumption or for any therapeutic, diagnostic, or clinical use. None of the items offered are classified as medicinal products by the MHRA. It is the buyer’s responsibility to ensure all purchases comply with applicable laws and regulations. Ascend Peptides UK accepts no liability for misuse.
